Tigulixostat is a medicine being tested to help people with gout, a condition that causes painful joints due to high levels of a substance called uric acid in the blood. This study will last for 12 months and will test three doses of Tigulixostat compared to another drug called Allopurinol and a placebo (a pill with no medicine) to see which works best. It is a double-blind study, meaning neither the doctor nor the patient will know which treatment they are receiving, to make sure the results are fair.

• The study lasts for 12 months.
• You may receive a new medicine, an existing treatment, or a placebo.
• Eligibility: Adults aged 18-85 with gout and specific blood uric acid levels.

Gout patients who want to participate must meet certain requirements, like having specific blood uric acid levels and not having an acute gout attack recently. Some people, like those with a history of xanthinuria or who have used certain treatments, won't be able to join. If you're interested, consider whether you meet the eligibility criteria and can commit to the study length.